Dear Reader,

The current issue features six contributions in the section ***Novel Vaccines***. Advances in herpes simplex vaccine development are reviewed (Coleman, p. 729), and three research papers evaluate a two-dose vaccination schedule for hepatitis B in animals (Li, p. 736), ways to increase the thermal stability of a ricin A chain subunit vaccine (Thomas, p. 744), and a *Treponema pallidum* DNA vaccine adjuvanted with CpG (Zhao, p. 753). This section also features a review on the recently published book "Development of novel vaccines" (Glenn, p. 761) and a commentary on whole-cell inactivated Leptospirosis vaccines (Verma, p. 763).

Several papers are related to ***Immunotherapy***: a study showing the co-stimulatory molecule 4-1BBL to enhance dendritic cell (DC)-mediated CTL activity (Youlin, p. 766), the effect of methionine encephalin combined with pidotimod on the maturation of DCs (Meng, p. 773), and the regulation of HLA-DR peptide occupancy by histone deacetylase inhibitors (Cronin, p. 784). This section also includes a review on the elimination of the latent HIV reservoir by reactivation strategies (Rasmussen, p. 790), and a number of commentaries discussing the identification of biomarkers in cancer vaccine development (Harrop, p. 800), mucosal Lactobacillus-vectored vaccines (Yu, p. 805), and short peptides as immunomodulators (Dong, p. 808).

The rubric ***Health Economics*** features papers on cost-effectiveness of childhood varicella-zoster virus vaccination (Bilcke, p. 812), epidemiological impact and disease cost-savings of HPV vaccines (Bresse, p. 823), key issues for estimating impact and cost-effectiveness of seasonal influenza vaccination strategies (Jit, p. 834), and employer-incurred health care costs and productivity losses associated with influenza (Karve, p. 841).

A wide range of papers fall in the category ***Licensed Vaccines***: clinical trial results of the live attenuated shingles vaccine (Vesikari, p. 858), effectiveness of the 23-valent pneumococcal polysaccharide vaccine in preventing hospitalization with influenza (Domínguez, p. 865), HPV vaccine uptake in US (Laz, p. 874), clinical trial results of the 17DD yellow fever vaccine (Martins, p. 879), memory response and safety of a booster dose of Japanese encephalitis chimeric virus vaccine (Feroldi, p. 889), and the effects of booster vaccination in children with combined hepatitis A and hepatitis B vaccine (Chen, p. 898). Commentaries discuss vaccination for typhoid fever in Sub-Saharan Africa (Slayton, p. 903) and the effects of exercise on vaccine-induced immune responses (Edwards, p. 907).

Two studies on ***Influenza Vaccines Uptake*** look at determinants of influenza vaccination uptake among health care workers (Barbadoro, p. 911) and pandemic influenza vaccination during pregnancy (Sammon, p. 917).

We are pleased to publish a group of meeting reports on the ***World Vaccine Congress 2012***, discussing challenges and impact of conducting vaccine trials in Asia and Africa (Kochhar, p. 924), developing novel vaccines for the emerging and developing markets (Kochhar, p. 928), and vaccinology capacity building in Europe for innovative platforms serving emerging markets (Hendriks, p. 932).

In the frame of our portrait series, we are pleased to present Dr William Grossman, Senior Vice President, Research & Development at the biotechnology company Biothera (MN, USA). Read his essay to learn more about his versatile career in the clinics, academia, and in industry.

As usual, our monthly News, Policy and Profiles (NP&P) section provides you with a selection of the latest news in the field of vaccines and immunotherapeutics. Our NP&P track is an excellent platform to share your opinion on timely, interesting and controversial topics in the field of vaccines and/or immunotherapy. It is also a good place to present your company or organization to an interested specialist audience. Please contact the Acquisitions Editor Eva Riedmann (eva\@landesbioscience.com) with your ideas for a commentary or if you would like to see your company/organization featured in a future issue of *HV&I*.

Finally, we want to draw your attention to several popular web site features, including an iPad application that allows you to read the full issue of *HV&I* anywhere, just as you would the print issue, an RSS feed to see the latest published papers, and a *HV&I* facebook account for daily updates.

Sincerely,

Ronald Ellis PhD

Editor-in-Chief

Eva M. Riedmann PhD

Acquisitions Editor
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